# Pembrolizumab and Paclitaxel in Hormone Receptor-positive, hyperMUTATted Metastatic Breast Cancer Identified by Whole exOme sequeNcing ('MUTATION2')

> **NCT04946227** · PHASE2 · UNKNOWN · sponsor: **Yonsei University** · enrollment: 52 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Pembrolizumab 200mg +Paclitaxel 80mg/m2

## Key facts

- **NCT ID:** NCT04946227
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-07
- **Primary completion:** 2022-12
- **Final completion:** 2022-12
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2021-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04946227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04946227, "Pembrolizumab and Paclitaxel in Hormone Receptor-positive, hyperMUTATted Metastatic Breast Cancer Identified by Whole exOme sequeNcing ('MUTATION2')". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04946227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*